Hey JS, what everyone is side stepping is the fact that Pascoe is betting "our" savings on Fispemifene. That is why this looks like Somaxon part II.
Let's do a breif history.....Damaj gave us all these examples of a deep pipeline using Nexact. We had MyCova, Prevonco, RayVa, Femprox and his OTC concept for pain medication using Nexact and insulin. Then, out of no where he buys Totect, Granisol and the rights to that nitro drug....all crap drugs with evaporating markets. What he told the street...Apricus touted a pipeline that is, and never will exist. Because if it did, why would you waste your R&D on these drugs.
Fast forward, Pascoe tells us it is all about V and Femprox. Then all of a sudden we have RayVa, then Femprox dissapears with a very poor reason from management. They could license EU/US to one company and let them start the trials in the EU. Then the old switch to RayVa. I was ok with that since you can place a value on an orphan drug. Orphan drug has 8 year market exclusivity before you need to defend patents from generics. Plus, you have pricing power. They would also have off label use for diabetic pain and circulation issues...reduction in amputations.
Now, all of a sudden they commit a large amount of resources to a drug that has been out there and tested that no one else has tried to take further since 2008. Which also has the potential to compete against a biosimilar drug that is off patent and tested since 2005...for the very same condition. What Pascoe has done is Damaj part II, telling the market that Apricus does not have a potential pipeline and Nexact has no further use past Alprostadil.
This is what I see and that is why I am trying to hold them accountable. Before this investment goes to zero. In Pascoe's defense, he has experience taking a 100 million dollar company through to a sale in the singles of millions. I doubt we get zero.
